Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success
Moderna and Merck have developed a cancer vaccine that has been highly effective in treating melanoma patients. In a late-stage trial, it reduced the risk of death and melanoma recurrence by 42% when paired with Keytruda. The problem is that the…